FCTDI is pleased to announce that it has been awarded a Phase I Contract SBIR from NIAID/NIH entitled “Combinations of Oral Antibiotics to Treat Syphilis”.
FCTDI Awarded Phase I Contract SBIR from NIAID/NIH
November 15, 2024
FCTDI is pleased to announce that it has been awarded a Phase I Contract SBIR from NIAID/NIH entitled “Combinations of Oral Antibiotics to Treat Syphilis”.